Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte.
Nunzia D'OnofrioLucia ScisciolaCelestino SarduMaria Consiglia TrottaMarisa De FeoCiro MaielloPasquale MascoloFrancesco De MiccoFabrizio TurrizianiEmilia MunicinòPasquale MonettiAntonio LombardiMaria Gaetana NapolitanoFederica Zito MarinoAndrea RonchiVincenzo GrimaldiAnca HermeneanMaria Rosaria RizzoMichelangela BarbieriRenato FrancoCarlo Pietro CampobassoClaudio NapoliMaurizio MunicinòGiuseppe PaolissoMaria Luisa BalestrieriRaffaele MarfellaPublished in: Cardiovascular diabetology (2021)
The upregulation of ACE2 expression (total and glycosylated forms) in DM cardiomyocytes, along with non-enzymatic glycation, could increase the susceptibility to COVID-19 infection in DM patients by favouring the cellular entry of SARS-CoV2.
Keyphrases
- sars cov
- poor prognosis
- end stage renal disease
- angiotensin ii
- respiratory syndrome coronavirus
- type diabetes
- ejection fraction
- newly diagnosed
- glycemic control
- chronic kidney disease
- angiotensin converting enzyme
- cardiovascular disease
- peritoneal dialysis
- minimally invasive
- prognostic factors
- binding protein
- signaling pathway
- long non coding rna
- nitric oxide
- skeletal muscle
- high glucose